Emergenza “L’Aquila2009”: la campagna di acquisizione dati della Rete Sismica Mobile stand-alone del Centro Nazionale Terremoti

Il 6 aprile 2009 (3.32 locali) un terremoto di Mw 6,3 ha colpito la regione Abruzzo (Italia centrale) producendo un enorme danno alla città de L'Aquila e ai paesi limitrofi causando circa 300 morti e 60.000 senza fissa dimora. A seguito di questo evento sismico, la struttura di Pronto Intervento dell’INGV (Istituto Nazionale di Geofisica e Vulcanologia), si è rapidamente attivata installando in area epicentrale due reti sismiche temporanee (Re.Mo.Tel. in real-time e Re.Mo. in stand-alone) ed il Centro Operativo Emergenza Sismica. In questo lavoro presentiamo come si e’ svolta la campagna sismica della Re.Mo., avente l’obiettivo di acquisire dati di alta qualità e dettaglio per studiare le sorgenti sismiche, l’evoluzione spazio temporale della sequenza e caratterizzare attraverso la microsismicita’ le strutture di faglia attivate ed le proprieta’ del mezzo circostante. Saranno descritte nel dettaglio l’installazione compiuta a poche ore dal mainshock, il suo sviluppo legato all’evoluzione della sequenza sismica, fino alla sua dismissione nel Marzo 2010.Istituto Nazionale di Geofisica e VulcanologiaPublished1.1. TTC - Monitoraggio sismico del territorio nazionaleope

Emergenza “L’Aquila2009”: la campagna di acquisizione dati della Rete Sismica Mobile stand-alone del Centro Nazionale Terremoti

Il 6 aprile 2009 (3.32 locali) un terremoto di Mw 6,3 ha colpito la regione Abruzzo (Italia centrale) producendo un enorme danno alla città de L'Aquila e ai paesi limitrofi causando circa 300 morti e 60.000 senza fissa dimora. A seguito di questo evento sismico, la struttura di Pronto Intervento dell’INGV (Istituto Nazionale di Geofisica e Vulcanologia), si è rapidamente attivata installando in area epicentrale due reti sismiche temporanee (Re.Mo.Tel. in real-time e Re.Mo. in stand-alone) ed il Centro Operativo Emergenza Sismica. In questo lavoro presentiamo come si e’ svolta la campagna sismica della Re.Mo., avente l’obiettivo di acquisire dati di alta qualità e dettaglio per studiare le sorgenti sismiche, l’evoluzione spazio temporale della sequenza e caratterizzare attraverso la microsismicita’ le strutture di faglia attivate ed le proprieta’ del mezzo circostante. Saranno descritte nel dettaglio l’installazione compiuta a poche ore dal mainshock, il suo sviluppo legato all’evoluzione della sequenza sismica, fino alla sua dismissione nel Marzo 2010

Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study

Objective Dravet syndrome (DS) is a drug-resistant, infantile onset epilepsy syndrome with multiple seizure types and developmental delay. In recently published randomized controlled trials, fenfluramine (FFA) proved to be safe and effective in DS. Methods DS patients were treated with FFA in the Zogenix Early Access Program at four Italian pediatric epilepsy centers. FFA was administered as add-on, twice daily at an initial dose of 0.2 mg/kg/d up to 0.7 mg/kg/d. Seizures were recorded in a diary. Adverse events and cardiac safety (with Doppler echocardiography) were investigated every 3 to 6 months. Results Fifty-two patients were enrolled, with a median age of 8.6 years (interquartile range [IQR] = 4.1-13.9). Forty-five (86.5%) patients completed the efficacy analysis. The median follow-up was 9.0 months (IQR = 3.2-9.5). At last follow-up visit, there was a 77.4% median reduction in convulsive seizures. Thirty-two patients (71.1%) had a >= 50% reduction of convulsive seizures, 24 (53.3%) had a >= 75% reduction, and five (11.1%) were seizure-free. The most common adverse event was decreased appetite (n = 7, 13.4%). No echocardiographic signs of cardiac valvulopathy or pulmonary hypertension were observed. There was no correlation between type of genetic variants and response to FFA. Significance In this real-world study, FFA provided a clinically meaningful reduction in convulsive seizure frequency in the majority of patients with DS and was well tolerated

Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study

Objective: Dravet syndrome (DS) is a drug-resistant, infantile onset epilepsy syndrome with multiple seizure types and developmental delay. In recently published randomized controlled trials, fenfluramine (FFA) proved to be safe and effective in DS. Methods: DS patients were treated with FFA in the Zogenix Early Access Program at four Italian pediatric epilepsy centers. FFA was administered as add-on, twice daily at an initial dose of 0.2 mg/kg/d up to 0.7 mg/kg/d. Seizures were recorded in a diary. Adverse events and cardiac safety (with Doppler echocardiography) were investigated every 3 to 6 months. Results: Fifty-two patients were enrolled, with a median age of 8.6 years (interquartile range [IQR] = 4.1-13.9). Forty-five (86.5%) patients completed the efficacy analysis. The median follow-up was 9.0 months (IQR = 3.2-9.5). At last follow-up visit, there was a 77.4% median reduction in convulsive seizures. Thirty-two patients (71.1%) had a ≥50% reduction of convulsive seizures, 24 (53.3%) had a ≥75% reduction, and five (11.1%) were seizure-free. The most common adverse event was decreased appetite (n = 7, 13.4%). No echocardiographic signs of cardiac valvulopathy or pulmonary hypertension were observed. There was no correlation between type of genetic variants and response to FFA. Significance: In this real-world study, FFA provided a clinically meaningful reduction in convulsive seizure frequency in the majority of patients with DS and was well tolerated